Glutamate Chemical Exchange Saturation Transfer (GluCEST) MRI to Evaluate the Rapid Antidepressant Effects of Ketamine in the Hippocampus of Rat Depression Model

© 2023 International Society for Magnetic Resonance in Medicine..

BACKGROUND: Ketamine is a quick acting antidepressant drug, and an accurate detection method is lacking. Ketamine's effects in a rat depression model have not previously been well explored using glutamate chemical exchange saturation transfer (GluCEST).

PURPOSE: To investigate the GluCEST changes of chronic unpredictable mild stress (CUMS) rats after receiving either ketamine or saline injection.

STUDY TYPE: Randomized animal model trial.

ANIMAL MODEL: 12 CUMS and 6 Sprague-Dawley rats. Divided into three groups: ketamine (N = 6), saline (N = 6), and control (N = 6).

FIELD STRENGTH/SEQUENCE: 7.0 T/the sequence is GluCEST and 1 H MR spectroscopy (MRS).

ASSESSMENT: The CUMS rats were exposed to different stress factors for 8 weeks. The glutamate concentration in the hippocampus was assessed by the GluCEST,1 H MRS, and the high-performance liquid chromatography (HPLC).

STATISTICAL TESTS: The t-test, Mann-Whitney U test, and Pearson's correlation.

RESULTS: In depression conditions, GluCEST signals were lower in the bilateral hippocampus than in control group. Thirty minutes after ketamine injection, the GluCEST signals in the bilateral hippocampus were higher compared with the saline group (left: 2.99 ± 0.34 [Control] vs. 2.44 ± 0.20 [Saline] vs. 2.85 ± 0.11 [Ketamine]; right: 2.97 ± 0.28 [Control] vs. 2.49 ± 0.25 [Saline] vs. 2.86 ± 0.19 [Ketamine]). In 1 H MRS, significant changes were only observed in the left hippocampus (2.00 ± 0.16 [Control] vs. 1.81 ± 0.09 [Saline] vs. 2.04 ± 0.14 [Ketamine]). Furthermore, HPLC results showed similar trends to those observed in the GluCEST results (left: 2.32 ± 0.22 [Control] vs. 1.96 ± 0.11 [Saline] vs. 2.18 ± 0.11 [Ketamine]; right: 2.35 ± 0.18 [Control] vs. 1.87 ± 0.16 [Saline] vs. 2.09 ± 0.08 [Ketamine]).

DATA CONCLUSION: GluCEST can sensitively evaluate the ketamine's antidepressant effects by detecting the fast increase in glutamate concentration.

LEVEL OF EVIDENCE: 1 TECHNICAL EFFICACY STAGE: 1.

Medienart:

E-Artikel

Erscheinungsjahr:

2024

Erschienen:

2024

Enthalten in:

Zur Gesamtaufnahme - volume:59

Enthalten in:

Journal of magnetic resonance imaging : JMRI - 59(2024), 4 vom: 26. März, Seite 1373-1381

Sprache:

Englisch

Beteiligte Personen:

Li, Hao [VerfasserIn]
Luo, Xunrong [VerfasserIn]
Qi, Kai [VerfasserIn]
Lv, Yijie [VerfasserIn]
Kan, Junnan [VerfasserIn]
Yang, Changfeng [VerfasserIn]
Lin, Xiaoqian [VerfasserIn]
Tao, Jin [VerfasserIn]
Zhang, Wei [VerfasserIn]
Liu, Yan [VerfasserIn]
Rong, Kang [VerfasserIn]
Wang, Ailing [VerfasserIn]
Jiang, Zhongde [VerfasserIn]
Li, Xianglin [VerfasserIn]

Links:

Volltext

Themen:

3KX376GY7L
690G0D6V8H
Antidepressive Agents
Depression
GluCEST
Glutamate
Glutamic Acid
HPLC
Journal Article
Ketamine
MRS

Anmerkungen:

Date Completed 12.03.2024

Date Revised 12.03.2024

published: Print-Electronic

Citation Status MEDLINE

doi:

10.1002/jmri.28921

funding:

Förderinstitution / Projekttitel:

PPN (Katalog-ID):

NLM359962033